crispr/cas9

Brefeldin A (Cyanein) belongs to the class of macrolide antibiotics and is an ATPase inhibitor (IC50=0.2 μM). Brefeldin A can induce tumor cell differentiation and apoptosis, and also possesses autophagy inhibitory activity.

Zidovudine (ZDV) is a synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines.

BRD20322 is a novel potent inhibitor of spCas9 that disrupts spCas9-DNA binding and exerts dose and temporal control of spCas9 in human cell lines. It reduces off-target DNA editing events, enhancing the precision and safety of CRISPR-Cas9 gene editing.

(iso)-BRD20322 is an isomer of BRD20322, a novel potent inhibitor of spCas9 that disrupts the binding of spCas9 to DNA and reduces non-specific DNA editing events, thereby improving the safety and accuracy of the CRISPR-Cas9 gene editing system.

SCR7 pyrazine (SCR7) enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).

BRD0539 is a cell-permeable spCas9 inhibitor that blocks the binding of spCas9 to DNA and inhibits Streptococcus pyogenes Cas9 (SpCas9).

Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.

SCR7, a specific DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ).

CEM114 is a potent chemical compound known as a chemical epigenetic modifier (CEM). It functions by employing CRISPR-Cas9 systems to harness endogenous chromatin machinery, thereby exerting its epigenetic modifying effects.

NU7441 (KU-57788 (NU7441)) is a highly effective and specific DNA-PK inhibitor (IC50: 14 nM).

L755507 is an effective, selective agonist of β3-AR(IC50=35 nM).

RS-1 is a RAD51 activator. RS-1 also increases CRISPR/Cas9-mediated knock-in efficiencies.

BRD7586 is a cell-permeable small molecule inhibitor of SpCas9 that enhances SpCas9 specificity.

Mca-VDQVDGW-Lys(Dnp)-NH2, a fluorogenic substrate specific to caspase-7, facilitates the quantification of caspase-7 activity.

Cas9-IN-3 is a potent inhibitor of Cas9 with an IC50 of 28 μM. The CRISPR/Cas systems have revolutionized gene editing in several species [1].

9A1P9, a multi-tail ionizable cationic phospholipid, facilitates membrane destabilization and is applicable for CRISPR-Cas9 gene editing in mice [1].

Cas9-IN-1 is a potent inhibitor of Cas9 with an IC50 value of 7.02 μM, acting by binding apo-Cas9 and blocking the formation of the Cas9:gRNA complex.

Cas9-IN-2 is a potent Cas9 inhibitor with an IC50 of 246 μM. It binds to apo-Cas9, thereby preventing the formation of Cas9:gRNA complexes. Cas9-IN-2 can be used to regulate and control Cas9 activity.

SpCas9 D10A Nickase is a variant of the Cas9 protein. This mutation retains the functionality of one cleavage domain of the Cas9 nuclease, allowing it to specifically nick a target single strand. Additionally, SpCas9 D10A Nickase is effective in reducing off-target effects.

AsCas12a Nuclease is a CRISPR nuclease capable of specifically cleaving double-stranded DNA. It is used in gene editing research.

N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide is an analogue of TT3 . TT3 is an ionizable lipid material utilized for the delivery of mRNA.

TT3 is an ionizable lipid-like material used for the delivery of mRNA and CRISPR/Cas9 [1] [2].

Peptide A5K acetate (INF7-A5K-TAT acetate) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold, designed to facilitate macromolecular transport in genome editing. Peptide A5K acetate non-covalently binds to CRISPR RNP (ribonucleoprotein complex) and delivers it into cells such as primary human T cells, B cells, and NK cells, enabling low-toxicity, multi-target, highly efficient, and precise genome editing.

CL4F8-6, an ionizable cationic lipid with a pKa of 6.14, is utilized in lipid nanoparticles (LNPs) for mRNA therapeutics. When incorporated into LNPs delivering Cas9 mRNA and sgRNA, CL4F8-6 facilitates CRISPR-mediated gene knockdown in mice [1].